Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety

Takla, Michael; Jeevaratnam, Kamalan

doi:10.1016/j.jsps.2020.11.003

Cited by 20 publications

(27 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another important consideration for patients with rCTDs during the pandemic is related to the fact that some rCTDs are treated with hydroxychloroquine. Reports of the potential of hydroxychloroquine 30 as a treatment for COVID-19 (ref. 7 ) created an increased demand that led to supply gaps in many countries, causing anxiety and fear among patients who rely on the drug.…”

Section: Effects Of Covid-19 On Rctd Carementioning

confidence: 99%

The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

Talarico

Aguilera²,

Alexander

et al. 2021

Nat Rev Rheumatol

View full text Add to dashboard Cite

Section: Effects Of Covid-19 On Rctd Carementioning

confidence: 99%

The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

Talarico

Aguilera²,

Alexander

et al. 2021

Nat Rev Rheumatol

View full text Add to dashboard Cite

“…In fact, hydroxychloroquine did not improve 28 day mortality in hospitalized COVID-19 patients (1,561 patients, 27% non-survivors) as compared to standard care (3,155 patients, 25% non-survivors) (98). A metaanalysis of studies on the efficiency of chloroquine for treating COVID-19 has shown that there was no significant difference in patient outcome and that the side effects posed a larger threat (99,107).…”

Section: Drugs and Vaccines Drugsmentioning

confidence: 97%

Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19

2021

View full text Add to dashboard Cite

The SARS-CoV-2 virus is causing devastating morbidity and mortality worldwide. Nanomedicine approaches have a high potential to enhance conventional diagnostics, drugs and vaccines. In fact, lipid nanoparticle/mRNA vaccines are already widely used to protect from COVID-19. In this review, we present an overview of the taxonomy, structure, variants of concern, epidemiology, pathophysiology and detection methods of SARS-CoV-2. The efforts of repurposing, tailoring, and adapting pre-existing medications to battle COVID-19 and the state of vaccine developments are presented. Next, we discuss the broad concepts and limitations of how nanomedicine could address the COVID-19 threat. Nanomaterials are particles in the nanometer scale (10–100 nm) which possess unique properties related to their size, polarity, structural and chemical composition. Nanoparticles can be composed of precious metals (copper, silver, gold), inorganic materials (graphene, silicon), proteins, carbohydrates, lipids, RNA/DNA, or conjugates, combinations and polymers of all of the aforementioned. The advanced biochemical features of these nanoscale particles allow them to directly interact with virions and irreversibly disrupt their structure, which can render a virus incapable of replicating within the host. Virus-neutralizing coats and surfaces impregnated with nanomaterials can enhance personal protective equipment, hand sanitizers and air filter systems. Nanoparticles can enhance drug-based therapies by optimizing uptake, stability, target cell-specific delivery, and magnetic properties. In fact, recent studies have highlighted the potential of nanoparticles in different aspects of the fight against SARS-CoV-2, such as enhancing biosensors and diagnostic tests, drug therapies, designing new delivery mechanisms, and optimizing vaccines. This article summarizes the ongoing research on diagnostic strategies, treatments, and vaccines for COVID-19, while emphasizing the potential of nanoparticle-based pharmaceuticals and vaccines.

show abstract

“…iii) Chloroquine (5-10 mg/kg/day for 5-10 days) was used in children with moderate to severe COVID disease in initial months of the pandemic [27]. However, latest evidence shows no role of chloroquine or hydroxychloroquine in treatment of COVID-19 [28].…”

Section: Kidney Function Test (Kft)mentioning

confidence: 99%

Pediatric Coronavirus Disease 2019: Clinical Features and Management

2021

View full text Add to dashboard Cite

There is a lack of clarity regarding management of COVID-19 infection in children. This review aims to summarize the key clinical presentations and management of Pediatric COVID-19. The Medline database was searched for seminal articles and guidelines on COVID-19 presentation and management in children less than 18 years of age. COVID-19 has a lower incidence (15% of reported cases worldwide), causes milder disease with lower need for intensive care admission and lower mortality rate (00.7%) in children compared with adults. Multisystem inflammatory syndrome is a rare but severe complication in children. Majority of patients require supportive care including adequate hydration, nutrition and antipyretics. Supplemental oxygen therapy should be given in moderate to severe cases with all precautions to prevent air-borne COVID-19 spread. Steroids may be helpful in severe cases. Anticoagulation is indicated in moderate to severe cases with risk factors. More data on the efficacy and safety of antivirals and immunomodulators in children is needed.

show abstract

Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety

Cited by 20 publications

References 99 publications

The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19

Pediatric Coronavirus Disease 2019: Clinical Features and Management

Contact Info

Product

Resources

About